Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alimera (ALIM) just unveiled an announcement.
Alimera Sciences, Inc. has entered into a definitive Merger Agreement with ANI Pharmaceuticals, Inc., under which Alimera will merge with ANI’s subsidiary and become a wholly owned indirect subsidiary of ANI. Shareholders of Alimera will receive $5.50 in cash and one contingent value right per share, which entitles them to additional payments based on future revenue milestones. The merger is contingent upon customary closing conditions, including regulatory approvals and a majority shareholder vote. Additionally, significant shareholders have entered a Voting Agreement to support the merger, and debt financing has been secured for the transaction.
Find detailed analytics on ALIM stock on TipRanks’ Stock Analysis page.